Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis.

Autor: Tang JP; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California., Lafeuille P; Medidata, a Dassault Systèmes Company, New York, New York., Socolov A; Medidata, a Dassault Systèmes Company, New York, New York., Diamond SS; Medidata, a Dassault Systèmes Company, New York, New York., Aptekar J; Medidata, a Dassault Systèmes Company, New York, New York., Moore TB; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California., Nie EH; Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California., Hanudel MR; Division of Pediatric Nephrology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California., Nowicki TS; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.; Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California.; Molecular Biology Institute, University of California Los Angeles, Los Angeles, California.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Oct 01; Vol. 4 (10), pp. 2589-2597.